Drug or treatment

Pertuzumab clinical trials

• 33Clinical trials
• 12Countries

Newest trials

All recruiting trials (33)

• Neoadjuvant Pyrotinib-to-pertuzumab for HER2-positive early breast cancer

  This trial tests whether a two-step neoadjuvant plan with Pyrotinib plus Trastuzumab and Docetaxel followed by Pertuzumab plus Trastuzumab and Docetaxel works better than four cycles of Pertuzumab plus Trastuzumab and Docetaxel in women with HER2-positive early- to locally advanced breast cancer.

  Recruiting Phase 3 Shanghai Jiao Tong University School of Medicine · Shanghai · NCT07797218

• Olaparib with Trastuzumab and Pertuzumab before surgery for older women with HER2-positive breast cancer

  This trial tests whether adding olaparib to standard HER2-targeted therapy can help older women with newly diagnosed, operable HER2-positive breast cancer before surgery.

  Recruiting Phase 4 Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT07695259

• Paclitaxel micelles with HER2-targeted therapy vs standard taxane-based therapy as first-line treatment for advanced HER2-positive breast cancer

  This study tests whether paclitaxel polymer micelles plus trastuzumab, pertuzumab, and ad Adelumab can better treat advanced HER2-positive breast cancer compared with the usual taxane-based therapy plus trastuzumab and pertuzumab.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07581795

• Using a pertuzumab biosimilar for HER2-positive breast cancer before surgery and as first-line treatment for metastatic disease

  This project will look at how a pertuzumab biosimilar is used and how patients with HER2-positive breast cancer do when given it before surgery or as first-line treatment for metastatic disease.

  Recruiting at 2 sites Société Algérienne de Formation et Recherche en Oncologie · Algiers and 1 other locations · NCT07542496

• BL-M07D1 plus pertuzumab vs standard therapy in first-line HER2-positive breast cancer

  A Phase 3 trial tests whether adding BL-M07D1 to pertuzumab is as good as or better than docetaxel plus trastuzumab and pertuzumab in patients with newly diagnosed, unresectable or metastatic HER2-positive breast cancer.

  Recruiting at 2 sites Phase 3 Sichuan Baili Pharmaceutical Co., Ltd. · Guangzhou, Guangdong and 1 other locations · NCT07518173

• KN026 plus HB1801 with chemotherapy as adjuvant treatment after surgery for resectable HER2-positive breast cancer

  This study will test whether giving KN026 and HB1801 with chemotherapy after surgery helps people with resectable HER2-positive breast cancer more than the usual trastuzumab plus pertuzumab with chemotherapy.

  Recruiting Phase 3 Shanghai JMT-Bio Inc. · Shanghai, Shanghai Municipality · NCT07441460

• Pre-surgery trastuzumab deruxtecan (SHR-A1811) plus pertuzumab for HER2-positive breast cancer

  This trial tests giving trastuzumab deruxtecan (SHR-A1811) with pertuzumab before surgery to see if it helps women with stage II–III HER2-positive breast cancer achieve a complete response.

  Recruiting Phase 2 Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality · NCT07393425

• IBI354 with or without pertuzumab versus taxane plus trastuzumab and pertuzumab for HER2-positive metastatic breast cancer

  This trial tests whether IBI354, with or without pertuzumab, works better than standard taxane plus trastuzumab and pertuzumab as first-line treatment for adults with HER2-positive unresectable locally advanced or metastatic breast cancer.

  Recruiting Phase 3 Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Beijing, Beijing Municipality · NCT07377643

• Intensified HER2-targeted treatment for people with a suboptimal response to initial dual HER2 therapy and chemotherapy

  This trial will try stronger targeted drug combinations for people with HER2-positive early breast cancer who don't respond well to initial dual HER2-targeted therapy plus chemotherapy.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou · NCT07340398

• Using blood ctDNA to compare two pre-surgery HER2-positive breast cancer regimens

  We will test whether two different pre-surgery drug combinations clear tumor DNA from the blood better in people with HER2-positive early breast cancer.

  Recruiting Phase 2 Shanghai Jiao Tong University School of Medicine · Shanghai · NCT07335081

• Subcutaneous trastuzumab‑pertuzumab before surgery for Algerian women with locally advanced HER2‑positive breast cancer

  This research will test whether giving the combined subcutaneous medicine Phesgo before surgery helps Algerian women with non‑metastatic HER2‑positive breast cancer clear invasive tumor from the breast and nearby lymph nodes.

  Recruiting Blida 1 University · Blida · NCT07166185

• Trastuzumab and pertuzumab biosimilars with XELOX before surgery for HER2-positive rectal cancer

  This tests whether adding trastuzumab and pertuzumab biosimilars to XELOX chemotherapy before surgery can increase the complete tumor response in adults with locally advanced HER2-positive rectal cancer.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing · NCT07108127

• Neoadjuvant oral paclitaxel with subcutaneous pertuzumab and trastuzumab for HER2-positive breast cancer

  This trial tests whether taking oral paclitaxel together with subcutaneous pertuzumab and trastuzumab before surgery helps people with HER2-positive breast cancer achieve a complete tumor response on pathology.

  Recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Beijing, Beijing Municipality and 8 other locations · NCT07095023

• TQB2102 versus docetaxel with trastuzumab and pertuzumab for HER2-positive recurrent or metastatic breast cancer

  This trial will test whether TQB2102 works as well as docetaxel plus trastuzumab and pertuzumab for adults with HER2-positive recurrent or metastatic breast cancer.

  Recruiting Phase 3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Hefei, Anhui and 24 other locations · NCT07003074

• Vaccine targeting HER2 in locally advanced breast cancer

  This trial will test a vaccine that boosts the immune system to attack HER2-positive breast cancer in adults with locally advanced or high-risk disease.

  Recruiting Phase 1 Indiana University · Indianapolis, Indiana · NCT06949410

• SHR-A1811 and pertuzumab before surgery for HER2-positive breast cancer

  This study tests whether adding SHR-A1811 to pertuzumab, with or without albumin-paclitaxel, helps people with early HER2-positive breast cancer reach a pathologic complete response before surgery.

  Recruiting Phase 2 Henan Cancer Hospital · Zhengzhou, Henan · NCT06927180

• Neoadjuvant BL-M07D1 (with or without pertuzumab) versus taxane + trastuzumab + pertuzumab for HER2-positive breast cancer

  This trial will try whether giving the experimental antibody BL-M07D1, with or without pertuzumab, before surgery improves outcomes for people with HER2-positive breast cancer compared with the standard taxane plus trastuzumab and pertuzumab regimen.

  Recruiting Phase 2/3 Sichuan Baili Pharmaceutical Co., Ltd. · Bengbu, Anhui and 29 other locations · NCT06891833

• Neoadjuvant therapy for low-risk HER2-positive breast cancer patients

  This study is testing a new treatment plan for people with low-risk HER2-positive breast cancer to see if combining certain chemotherapy drugs with targeted therapy can work just as well with less intense treatment.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT06722599

• Combination therapy for HER2-positive breast cancer

  This study tests a new combination of treatments for people with HER2-positive breast cancer to see if it helps them respond better before surgery.

  Recruiting Phase 2 RemeGen Co., Ltd. · Shanghai, Shanghai Municipality · NCT06178159

• Neoadjuvant treatment for HER2-positive breast cancer without chemotherapy

  This study is testing a new treatment using tucatinib, trastuzumab, and pertuzumab for people with stage II-III HER2-positive breast cancer to see if they can be treated without chemotherapy.

  Recruiting Phase 1 The Netherlands Cancer Institute · Amsterdam · NCT06162559

• Short-course treatment for early HER2-positive breast cancer

  This study is testing a shorter treatment plan with two medications for early HER2-positive breast cancer to see if it works just as well as the usual year-long treatment but with fewer side effects.

  Recruiting Phase 2 Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality · NCT05891561

• New treatment for HER2-positive recurrent or metastatic breast cancer

  This study is testing a new combination treatment for people with HER2-positive recurrent or metastatic breast cancer to see if it works better than the standard treatment.

  Recruiting Phase 3 Shanghai JMT-Bio Inc. · Beijing, chaoyang · NCT05838066

• Combination of trastuzumab and pertuzumab for treating cancers with HER2 mutations

  This study is testing if a combination of two cancer drugs, trastuzumab and pertuzumab, can help adults and young people with cancers that have HER2 mutations or amplifications.

  Recruiting at 24 sites Phase 2/3 Cancer Research UK · Belfast and 26 other locations · NCT05786716

• Treatment for hormone receptor positive HER2 positive breast cancer after neoadjuvant therapy

  This study is testing if combining two drugs, trastuzumab and nelatinib, can help people with hormone receptor positive HER2 positive breast cancer who still have cancer after initial treatment feel better compared to the usual combination of trastuzumab and pertuzumab.

  Recruiting Phase 3 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou · NCT05760612

• Neoadjuvant therapy for HER2-positive early breast cancer

  This study is testing if a new drug called trastuzumab-deruxtecan can work better than standard chemotherapy for people with early HER2-positive breast cancer to see if it helps them respond better to treatment.

  Recruiting at 40 sites Phase 2 Women's Cancer Study Group GmbH · Baden-Baden, Baden-Wurttemberg and 43 other locations · NCT05704829

• Combination treatment for HR+/HER2+ breast cancer

  This study is testing a new combination treatment for patients with stage II-III HR+/HER2+ breast cancer to see if it works better than the standard treatment before surgery.

  Recruiting Phase 2 Shengjing Hospital · Shenyang, Liaoning · NCT05638594

• HER2-targeted vaccine combined with standard chemotherapy for breast cancer

  This study is testing if adding a new vaccine to standard chemotherapy can help people with HER2-positive breast cancer have better treatment results.

  Recruiting Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT05325632

• Neoadjuvant therapy with or without Inavolisib for early HER2-positive breast cancer

  This study is testing if adding a new drug called Inavolisib to standard treatment can help women with early HER2-positive breast cancer respond better before surgery.

  Recruiting at 53 sites Phase 2 GBG Forschungs GmbH · Essen, North Rhine-Westphalia and 61 other locations · NCT05306041

• Using trastuzumab and pertuzumab to improve survival in HER2+ esophageal cancer

  This study is testing if adding two targeted therapies, trastuzumab and pertuzumab, to standard treatment can help people with HER2-positive esophageal cancer live longer.

  Recruiting Phase 3 Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Amsterdam · NCT05188313

• Comparing two treatment regimens for HER-2 positive breast cancer

  This study is testing two different treatment plans for people with HER-2 positive breast cancer to see which one works better before surgery.

  Recruiting Phase 3 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guandong, Guangdong · NCT05159193

• Treatment adjustment for HER2 positive breast cancer after initial therapy

  This study is testing if adjusting treatment for early HER2 positive breast cancer based on blood tests can help patients do better after their initial therapy.

  Recruiting Phase 2 AC Camargo Cancer Center · São Paulo · NCT04993014

• Combining Pyrotinib and ARX788 for treating HER2-positive breast cancer

  This study is testing a new combination of two drugs, pyrotinib and ARX788, to see if it can help women with stage II-III HER2-positive breast cancer who haven't responded well to other treatments.

  Recruiting Phase 2 Shengjing Hospital · Shenyang, Liaoning · NCT04983121

• Evaluating a new treatment approach for operable HER2-positive breast cancer

  This study is testing a new combination of medications and chemotherapy before surgery to see if it helps people with HER2-positive breast cancer achieve better treatment results.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT04281641

Quick answers

How many clinical trials of Pertuzumab are recruiting right now?

33, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 12 countries. The most sites are in China (23 trials), Algeria (2 trials), Germany (2 trials), Netherlands (2 trials), United States (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 14, Phase 3: 9, Phase 1: 2, Phase 2/3: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →